Market research
XERS Xeris Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 11.7143
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US98422E1038
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 11.7143
- Dividend yield
- Not available
- Beta
- 0.85
About
About Xeris Pharmaceuticals Inc
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the XERS discussion.
5 years, 4 months ago
Xeris Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 16.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.1.
Xeris Pharmaceuticals, Inc's total revenue rose by 291.7% to $7M since the same quarter in the previous year.
Its net income has increased by 33.9% to $-22M since the same quarter in the previous year.
Finally, its free cash flow grew by 62.8% to $-11M since the same quarter in the previous year.
Based on the above factors, Xeris Pharmaceuticals, Inc gets an overall score of 4/5.